Pharma Veteran Annalisa Jenkins On Gene Therapy And Patient-centric Drug Development

Annalisa Jenkins joined Dimension Therapeutics, a small biotech based in Cambridge, MA, as CEO after leading global research and development at Merck Serono, a large German pharmaceutical company. This jump from big pharma culture to niche biotech gives Jenkins a unique perspective on the state of drug development. Dimension focuses primarily on gene therapies for rare diseases, which Jenkins says is in line with what she views as an evolution in the biopharma space towards patient-centric drug development.

from Forbes – Business
via Abogado Aly Business Consulting

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s